Drug intelligence / Profile preview

AU2-85

Development stage: Preclinical
Lead developer: Aucentra Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

AU2-85 is an orally bioavailable, highly selective small molecule inhibitor of cyclin-dependent kinase 8 (CDK8), currently in late preclinical development by Aucentra Therapeutics for the treatment of haematological malignancies. The drug functions by modulating the transcriptional regulation of cytokines through the STAT1/5 pathway, a mechanism that disrupts tumor-promoting immune responses and gene expression in cancer cells. Preclinical studies in animal models have shown promising efficacy and safety profiles, supporting its potential as a targeted therapy for blood-borne cancers.

Targets

CDK8 (Cyclin-dependent kinase 8)

Beyond the preview

Go deeper on AU2-85.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AU2-85.

Explore the full profile